Whole‐body MRI surveillance in TP53 carriers is perceived as beneficial with no increase in cancer worry regardless of previous cancer: Data from the Swedish TP53 Study

Author:

Omran Meis12ORCID,Johansson Hemming1,Lundgren Claudia3,Silander Gustav4,Stenmark‐Askmalm Marie5,Loman Niklas67,Baan Annika8,Adra Jamila8,Kuchinskaya Ekaterina9,Blomqvist Lennart1011,Tham Emma1012,Bajalica‐Lagercrantz Svetlana1212,Brandberg Yvonne1,

Affiliation:

1. Department of Oncology‐Pathology Karolinska Institutet Stockholm Sweden

2. Cancer Theme Karolinska University Hospital Solna Stockholm Sweden

3. Department of Immunology, Genetics and Pathology Uppsala University Hospital Uppsala Sweden

4. Department of Radiation Sciences Umeå University Umeå Sweden

5. Division of Clinical Genetics Department of Laboratory Medicine Office for Medical Services Skåne University Hospital Lund Sweden

6. Division of Oncology and Pathology Department of Clinical Sciences Lund University Lund Sweden

7. Department of Hematology, Oncology and Radiation Physics Skåne University Hospital Malmö Sweden

8. Department of Oncology Sahlgrenska University Hospital Gothenburg Sweden

9. Department of Clinical Genetics Linköping University Hospital Linköping Sweden

10. Department of Molecular Medicine and Surgery Karolinska Institutet Stockholm Sweden

11. Department of Imaging and Physiology Karolinska University Hospital Solna Stockholm Sweden

12. Clinical Genetics Karolinska University Hospital Stockholm Sweden

Abstract

AbstractBackgroundTo evaluate the psychosocial consequences of surveillance with whole‐body MRI (WB‐MRI) in individuals with the heritable TP53‐related cancer (hTP53rc) syndrome, also known as the Li‐Fraumeni syndrome, with regard to cancer worry, perceived benefits and risks to surveillance and overall health.Patients and methodsSince 2016, the national Swedish TP53 Study (SWEP53) has offered surveillance with WB‐MRI to all individuals with hTP53rc syndrome. Seventy‐five individuals have been included in the study. Sixty consecutive participants fulfilled a base‐line evaluation as well as an evaluation after 1 year with structured questionnaires including the Cancer Worry Scale (CWS), perceived benefits and risks of surveillance, and the 36‐item Short Form Survey (SF‐36). Individuals with or without previous personal cancer diagnosis were enrolled and results at baseline and after 1 year of surveillance were compared. For SF‐36, a comparison with the normal population was also made.ResultsParticipants with previous cancer tend to worry more about cancer, but both individuals with and without cancer had a positive attitude toward surveillance with no differences regarding perceived benefits and barriers to surveillance. Participants with a previous cancer scored significantly lower on some of the SF‐36 subscales, but between‐group differences were found only for social functioning after 1 year.ConclusionsSurveillance with WB‐MRI is feasible from a psychosocial point of view both among TP53 carriers with as well as without a previous history of cancer and does not increase cancer worry in any of the groups.Plain language summary Individuals with heritable TP53‐related cancer syndrome (also known as the Li‐Fraumeni syndrome) have a high lifetime risk of developing cancer. These TP53 carriers are offered surveillance with whole‐body MRI to detect cancer early. There are few reports of the psychosocial impact of surveillance. In this study, we wanted to evaluate cancer worry, benefits and barriers to participation, and perceived overall health. Our study shows no increase in cancer worry after 1 year of surveillance, regardless of previous cancer.

Publisher

Wiley

Subject

Cancer Research,Oncology

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. A Comprehensive Overview of Various Cancer Types and Their Progression;Handbook of Oncobiology: From Basic to Clinical Sciences;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3